Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO).
read morePress Releases
Anaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting
Anaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA.
read moreAnaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022
Anaveon appoints Dr Gary Phillips as Chief Business Officer
Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions.
read moreAnaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419
Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma.
read moreAnaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
As of the March 11, 2022 data cut-off date, 16 patients in 7 dosing cohorts with different types of progressing cancer received ANV419 every 14 days. ANV419, administered intravenously over 15 minutes was exceptionally well tolerated with most patients experiencing a mild Grade 1 infusion-related reaction with chills and low-grade fever a few hours after dosing, which resolved with antipyretic treatment. No patients experienced a Grade 3 or worse drug related AE and no patients have withdrawn from study due to AEs. No dose limiting toxicities have been observed.
read moreAnaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022
Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisana, April 8 to April 13, 2022.
read moreAnaveon to raise CHF 110 million in oversubscribed Series B financing
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.
read more